<DOC>
	<DOCNO>NCT00505219</DOCNO>
	<brief_summary>The purpose study determine Ixmyelocel-T graft demineralize bone matrix bound autologous plasma core decompression surgery superior core decompression demineralize bone matrix bound autologous plasma prevent progression osteonecrosis severe disease stage ( Stage II III high ) time surgery 24 month later , patient University Pennsylvania ( UPenn ) Stage IIB C disease diagnosis .</brief_summary>
	<brief_title>Ixmyelocel-T Treatment Patients With Osteonecrosis Femoral Head</brief_title>
	<detailed_description>This study event-driven , multi-center , prospective , independent observer-blinded , control , randomized Phase III clinical trial enrol patient diagnosed University Pennsylvania ( Steinberg ) Classification Stage IIB C osteonecrosis femoral head . - The first patient group Treatment Group receive core decompression treatment BRCs demineralize bone matrix bound autologous plasma , - The second patient group Control Group receive core decompression demineralize bone matrix bound autologous plasma , without BRCs . - Enrollment : With anticipated drop-out rate 10 % twenty ( 20 ) site , total approximately 135 patient enrol randomized obtain 120 evaluable patient ( 75 TRC treatment group 45 Control treatment group ) . - Primary endpoint : The percentage patient progress severe UPenn disease stage ( Stage II III high ) 0 24 month primary efficacy variable demonstrate TRC therapy superior Control therapy .</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>UPenn ( Steinberg ) classification osteonecrosis , inclusive Stages IIB IIC . Diagnosis base magnetic resonance imaging ( MRI ) . Modified index necrotic extent &lt; 40 Idiopathic nonidiopathic osteonecrosis . No infection affect bone time surgery . Patient competent give inform consent . Normal organ marrow function define : Leukocytes ≥ 3000/µL ; Absolute neutrophil count ≥ 1500/µL ; Platelets ≥ 140,000/µL ; Serum AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional standard range ; Serum creatinine within normal limit , base clinical laboratory normal range . Female patient pregnant lactate . Patients history corticosteroid active therapy , eligible enrollment corticosteroid use suspend 1 month prior 6 month cell therapy surgery . Patients treat oral bisphosphonates eligible trial treatment stop least 6 month prior enrollment . Stages IA , IB , IC , IIA , IIIA severe femoral head osteonecrosis , primarily base diagnosis MRI . Flattening femur head ( UPenn Stage IV ) articular cartilage collapse time core decompression surgery . Septic arthritis ; stress fracture , nonosteonecrosis metabolic bone disease ( e.g. , Paget 's disease bone , osteogenesis imperfecta , primary hyperparathyroidism , fibrous dysplasia [ monostotic , polyostotic McCuneAlbright syndrome ] osteopetrosis ) . Any active bisphosphonate treatment history intravenous ( IV ) treatment HIV , syphilis , positive time screen . Active hepatitis B hepatitis C infection time screen Known allergy protein product ( horse bovine serum , porcine trypsin ) . Patients require continuous , systemic , high dose corticosteroid therapy ( 7.5 mg/day ) within 6 month surgery . Patients active treatment cancer blood dyscrasia , receive chemotherapy , radiotherapy immunotherapy past 2 year . Immunodeficiency disease . Participation another clinical study past 30 day concurrent participation another clinical trial . History regular alcohol consumption exceed 2 drinks/day ( 1 drink = 5 oz [ 150 mL ] wine 12 oz [ 360 mL ] beer 1.5 oz [ 45 mL ] hard liquor ) within 6 month screen and/or history illicit drug use . MRIincompatible internal device ( pacemaker , aneurysm clip , etc ) Body mass index ( BMI ) 40 Kg/m2 great Patients unable tolerate general anesthesia define American Society Anesthesiologists ( ASA ) criteria &gt; 2 Patients poorly control diabetes mellitus ( HbA1C &gt; 8 % ) , peripheral neuropathy , know concomitant vascular problem . Patients receive treatment hematopoietic growth factor antivasculogenesis antiangiogenesis treatment Traumatic osteonecrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osteonecrosis</keyword>
</DOC>